Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers
BRB-002 was safe at all doses tested, with no SAEs reportedPhase 2 proof-of-concept study in patients with established atherosclerosis is expected to initiate in 1H 2025 PALO ALTO, Calif. and NEEDHAM, ...
Medscape3d
Immune Modulation And Increased Neurotrophic Factor Production In Multiple Sclerosis Patients Treated With Testosterone
It has been suggested that novel treatment options are needed that target both aspects of the disease. Evidence from basic and clinical studies suggests that testosterone has an immunomodulatory ...
Nasdaq27d
Aditxt Advances ADI-100 Therapy to Human Trials
Aditxt, Inc.’s subsidiary, Adimune, Inc., has completed preclinical studies for its ADI-100 immune modulation therapy, positioning it for human trials targeting Type 1 Diabetes, Psoriasis ...
BioWorld27d
Adimune completes preclinical efficacy and safety studies of immune modulation therapy ADI-100
Adimune Inc., a subsidiary of Aditxt Inc., has successfully completed preclinical studies for its antigen-specific gene therapy, ADI-100. BioWorld Science Dermatologic Endocrine/metabolic Immune ...
Hosted on MSN1d
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...
News Medical1mon
Cancer therapy may raise heart attack and stroke risks by disrupting immune regulation in arteries
These patterns suggested distinct immune modulation roles within the plaque ... cancer patients undergoing immune checkpoint inhibitor treatment and offered a foundation for designing safer ...